Aquestive reports positive topline PK data for Anaphylm self-administration study

Aquestive Therapeutics, Inc.

Self-administration PK study met primary endpoints; PK comparable whether administered by subjects or HCPs.
Median Tmax of 15 minutes for Anaphylm self-admin & HCP-admin vs 50 minutes for Adrenalin IM injection in 36 healthy adults.
Remaining supportive OAS challenge study underway, expected completion late Q3 or early Q4 2024.
Company maintains NDA filing guidance late Q4 2024/early Q1 2025 and product launch by end 2025 or Q1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.